Study on faster recovery after heart procedure pulled before starting
NCT ID NCT05468957
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if using a special pad along with a standard closure device could help patients get out of bed sooner after a heart catheterization. It was planned for adults having the procedure through the groin. However, the study was withdrawn before any participants were enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Started
-
Aug 2022
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient undergoing diagnostic angiography or PCI with femoral access who undergo PercloseTM closure. * Catheterization with a 6Fr system * Those with a planned radial approach will also be enrolled given the possibility of changing to femoral access in the catheterization lab if radial access is not possible given radial artery spasm, significant patient discomfort with a contraindication to greater levels of sedation, inability to transverse guidewire into the aortic root, inability to engage coronary artery or deliver equipment, or other clinically indicated reason. Exclusion Criteria: \- Candidates for this study will be excluded if any one of the following criteria is true: * Use of a hemostasis method or device besides PercloseTM (Perclose may not be used in situations of heavy calcification, presence of dissection, etc). * Patients undergoing catheterization only from the radial, brachial, ulnar, or distal radial (snuffbox) artery approach. * Use of an anticoagulant other than unfractionated heparin or bivalirudin. * Any use of glycoprotein inhibitors or cangrelor. * Use of sheathless guides. * Any anticipated need for continued anticoagulation post-catheterization, including extended bivalirudin infusion. * Any active treatment with oral anticoagulants continued during course of procedure. * Presence of arteriovenous dialysis fistula in the ipsilateral leg. * Any physical deformity or trauma / injury of the leg that would prevent proper placement or function of the hemostasis band. * Inability of the patient to personally consent for the study. (no surrogate consent) * Cardiogenic shock, emergent procedures (high risk myocardial infarctions), or any clinical instability as assessed by the physician performing the procedure.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Arterial occlusion are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA Ronald Reagen
Los Angeles, California, 90025, United States
-
UCLA Santa Monica
Los Angeles, California, 90025, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could monthly texts and automatic risk scores stop heart attacks before they start?
- Can a nurse and a neighbor help tame chronic disease?
- Two eggs a day put to the test for heart health
- A soft patch that watches your heart beat in real time
- Can a Once-Daily form of tacrolimus spare liver transplant patients from side effects?
- Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs